- Home
- AGEN
AGEN
Agenus Inc.
as 04-22-2025 4:00pm EST
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 38.1M | IPO Year: | 2000 |
| Target Price: | $8.00 | AVG Volume (30 days): | 655.0K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -10.59 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.38 - $19.69 | Next Earning Date: | 05-06-2025 |
| Revenue: | $103,463,000 | Revenue Growth: | -33.81% |
| Revenue Growth (this year): | 4.03% | Revenue Growth (next year): | 5.57% |
Latest Agenus Inc. News
AGEN Breaking Stock News: Dive into AGEN Ticker-Specific Updates for Smart Investing
Business Wire
a month ago
Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025
Zacks
a month ago
Here's Why Agenus (AGEN) Is a Great 'Buy the Bottom' Stock Now
Business Wire
a month ago
Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation
GuruFocus.com
a month ago
Agenus Inc (AGEN) Q4 2024 Earnings Call Highlights: Strategic Moves Amid Financial Challenges
Thomson Reuters StreetEvents
a month ago
Q4 2024 Agenus Inc Earnings Call
Motley Fool
a month ago
Agenus (AGEN) Q4 2024 Earnings Call Transcript
Zacks
a month ago
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates
Associated Press Finance
a month ago
Agenus: Q4 Earnings Snapshot
Compare AGEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AGEN Agenus Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.